Skip to main content
Premium Trial:

Request an Annual Quote

Marina Licenses Delivery Technology Rights to ProNai

Premium

Marina Biotech said this week that it has signed an agreement giving DNA oligo drug firm ProNai Therapeutics the exclusive rights to its Smarticle delivery technology for DNA-based drug development.

Under the terms of the deal, Marina could receive up to $14 million for each gene target selected by ProNai, as well as royalties on product sales.

Additional terms were not disclosed.

Marina acquired the Smarticle technology from Novosom for $5 million in stock in 2010 (GSN 7/29/2010).

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.